The Japanese legal system covers two types of intellectual property rights in relation to the protection of inventions: patent rights and utility model rights. Both systems are based on statutory laws, namely the Patent Act and the Utility Model Act.
Patents
The Patent Act employs a substantive examination principle for the patent grant procedure. A patent application must first be filed with the Japan Patent Office (JPO) to obtain a patent right for an invention. A request for examination must also be filed within three years from the date of filing the patent application, or the patent application will be deemed withdrawn.
A JPO examiner conducts an examination to determine whether the patent application satisfies all requirements under the Patent Act.
Utility Models
In contrast to patent applications, the Utility Model Act does not require a substantive examination for applications for utility model registration (ie, for all applications that have passed formal examinations); the utility model right will be automatically registered without a substantive examination. The registration fees for the first three years must be paid at the time of filing the utility model application.
Patents
According to statistics issued by the JPO, the average period from filing a request for examination to the issuance of a final decision (either granting or rejecting) was 13.0 months in 2024. Also, the average grant rate was 76.3% in 2024.
Domestic applicants do not need representation in order to initiate grant proceedings, but foreign applicants do. The typical costs incurred from filing to grant are USD8,000, comprising official fees of USD1,500 and lawyers’ fees of USD6,500. The official fees vary depending on the number of claims. Also, additional fees for translating certain documents (eg, the specification and notice of the reason for rejection) may be incurred where necessary.
Utility Models
The typical costs incurred from filing to grant are USD2,000, comprising official fees of USD200 and lawyers’ fees of USD1,800. The official fees vary depending on the number of claims. Also, additional fees for translating certain documents (eg, the specification) may be incurred where necessary.
Patents
The term of a patent right is 20 years from the date of filing the patent application. There are, however, some exceptions:
Utility Models
The term of a utility model right is ten years from the date of filing the utility model application. A utility model application or right may be converted to a patent application within three years from the date of filing the utility model application.
Both patent and utility model owners have the right to an injunction, claim damages, and claim for unjust enrichment. Also, patent and utility model owners are obligated to pay annual renewal fees to maintain their rights.
Notably, a substantive examination is not required for utility model registration applications. As a result, a utility model owner can only enforce their rights against an infringer after issuing a warning and providing a Utility Model Technical Opinion Report for the registered utility model. This report assesses the novelty and inventive step of the registered utility model, conducted by a JPO examiner based on a search of prior art documents. A request for a Utility Model Technical Opinion Report can be made at any time after the application for a utility model has been submitted.
In Japan, there is no publicly available list of applicable patents for certain products or processes. Although there is a public database of patent information in Japan called J-PlatPat, J-PlatPat does not have any functions to search applicable patents in relation to certain products or processes.
In Japan, the patent linkage system is not established by statute but operates through administrative practice under a ministry notice issued by the Ministry of Health, Labour and Welfare (the “MHLW”). It essentially consists of two stages. First, marketing approval for a generic drug will not be granted if a patent exists for the active ingredient, or if certain indications or dosage regimens remain under patent, approval will be limited to the unpatented uses. Second, after approval and before price listing, the notice requires the generic manufacturer to hold a “prior consultation” with the patentee whenever any patent-related concern arises, to address those concerns and confirm a stable supply of the generic product upon market entry.
Unlike the U.S. Orange Book system, Japan has no official mechanism for publishing drug-related patents. In the first stage, the MHLW bases its decision on patent information voluntarily submitted by the originator; information not submitted will not be considered. The MHLW does not have the authority to make substantive determinations on patent infringement or validity. Nevertheless, its approval decisions inevitably affect the exercise of patent rights. Recognising this, the MHLW is introducing a new system in a pilot, announced in a recent ministry notice issued in November 2025, under which the MHLW may seek the views of a specialised advisory committee to incorporate expert opinions on pharmaceutical patents when reviewing generic or biosimilar drug applications for approval. The ministry’s notice regarding the patent linkage system mentioned above was also updated in October 2025 to clarify certain long-standing practices, including its application to biosimilars. As such, discussions around Japan’s patent linkage system are ongoing, and its future development deserves close attention.
There is no further protection for technical intellectual property rights after their maximum term has lapsed.
Anyone may file a third-party observation at any time after filing a patent application or an application for utility model registration, even after a patent or utility model right has been granted. Third-party observations may include prior art information or a submitter’s comments regarding the novelty or inventive step of the claimed inventions, as well as other information or comments regarding other requirements, such as the addition of new matter, the support requirement, or the enablement requirement. Third-party observations may be filed anonymously.
Patents
An applicant may file an appeal with the JPO against a rejection decision issued by a JPO examiner. A panel of three appeal examiners will then review the patent application to determine whether the rejection decision was appropriate.
When filing an appeal against the rejection, the applicant can amend the claims, specifications, or drawings. If any amendments are made, the application will first be re-evaluated by the initial examiner who issued the rejection decision before it is sent to the appeal board.
If the initial examiner finds that the amended application has been sufficiently improved, they may issue a decision to grant the application without further involvement from the appeal board. However, if the initial examiner still believes the application should be rejected, it will be forwarded to the appeal stage for examination by the panel of appeal examiners.
Utility Models
No remedy is available or applicable for utility model applications because the Utility Model Act does not require a substantive examination for the granting of a utility model right.
Patent or utility model owners who miss the annual fee deadline may still pay late by remitting both the annual fee and an equal surcharge within six months after the deadline expires.
Furthermore, if the patent owner or the utility model owner is unable to meet the payment deadline, they can still make an additional payment to restore the patent right or the utility model right, except in the case of a “willful” failure to meet the payment deadline. This additional payment can be made within two months of the applicant’s ability to make the payment or within one year after the payment deadline, whichever comes first.
Both patent and utility model owners may file a request for a trial to correct the description, the scope of the claims or the drawings attached to the application.
The purpose of the correction is limited to the following:
The correction cannot be made beyond the scope of the matters disclosed in the description, the scope of claims or the drawings attached to the application.
Utility model owners are allowed to make a request for correction only once, except for the deletion of claims, whereas patent owners may request a trial for correction as many times as they wish, except where the patent has been invalidated by an invalidation trial or revoked by a patent opposition. Patentees may not request a correction while a patent opposition or invalidation proceeding is pending but may instead request a correction in the proceedings of the patent opposition or patent invalidation trial.
If the owner of a technical intellectual property right (eg, a patent) finds that a third party is infringing upon their patent, they can take one or more of the following actions:
Only an interested person may file a request for a trial on patent invalidation. The term “interested person” means a person who has, or potentially will have, their legal interest/standing directly affected by the existence of the patent right. Conversely, in the Patent Opposition System, any person (not limited to interested persons) may file an opposition to a patent within six months of the publication date of the Gazette containing the patent.
The Japanese Patent Act also provides for three types of non-exclusive licences granted by the JPO Commissioner’s award (eg, compulsory licences). In 2021, a request for a compulsory license was filed for Japanese Patent No 6518878, marking the first time a council was convened in Japan to address such a request. However, in 2024, the parties reached a settlement, resulting in the withdrawal of the request. As of the end of 2025, no compulsory license has been granted in Japan.
The Tokyo and Osaka District Courts have exclusive jurisdiction over first-instance patent and utility model rights litigation. The court where a plaintiff should file a lawsuit depends on the defendant’s corporate address and the location of the infringing activity. The Japanese Intellectual Property High Court (IPHC) has exclusive jurisdiction over appeals from District Court decisions. The IPHC is a special branch of the Tokyo High Court. Parties may appeal the IPHC’s decisions to the Supreme Court.
The Japan Intellectual Property Arbitration Centre (JIPAC) provides alternative dispute resolution services, including mediation and arbitration, in the field of intellectual property. In addition, the International Arbitration Centre in Tokyo (IACT) – an international arbitration organisation expected to provide dispute resolution services – commenced operations in September 2018.
There are no statutory prerequisites for filing a lawsuit. However, as patent rights and registered exclusive licences become effective upon the establishment of registration with the JPO, such registration will be required when a patentee or registered exclusive licensee brings a claim for damages and/or an injunction based on that patent right or registered exclusive licence. It is, however, generally considered that such registration will not be required when a non-registered exclusive licensee brings a claim for damages based on a non-registered exclusive licence.
In Japan, a party may choose at their own discretion whether to have legal representation. However, in practice, it is common for lawyers to represent parties in intellectual property matters. Patent lawyers can also represent parties for certain intellectual property cases under certain conditions.
In Japan, preliminary injunctions are available in cases where such injunctions are necessary to prevent a rights owner from incurring substantial detriment or an imminent danger with respect to the rights in dispute. If a request for a preliminary injunction is granted, the rights owner will usually be required to deposit a certain amount of money as security. The court will determine the amount of that security in consideration of the circumstances of the specific case. A relatively large amount of money may be required to be deposited as security.
As the preliminary injunction substantially achieves an injunction against the other party’s conduct before the lawsuit is finalised, in a preliminary injunction case, a hearing of both the rights-owner and the other party is required, and prima facie evidence of a similar level to the proof required in the lawsuit is often required. In general, preliminary injunctions are intended to resolve disputes more quickly than litigation; however, the speed of trial is often not so different from that of litigation because of the need for prima facie evidence, as mentioned above.
A potential defendant can file a request for a patent invalidation trial before the JPO and/or initiate a lawsuit for a declaratory judgment to confirm the absence of the right to demand an injunction, etc. There is no need for a potential opponent to lodge a protective brief in order to take these actions. It should be noted that a potential opponent is not entitled to require the owner to post a bond under the Civil Preservation Act, but a court usually orders the owner to deposit a certain amount as security when issuing an interim injunction order.
There are no special limitations applicable only to intellectual property matters.
Claims for injunctions based on patent rights may be filed at any time if infringement of the patent rights exists or a threat of infringement of the patent rights is recognised.
The claim for compensation for loss or damage by the tort of patent infringement is extinguished by prescription if the right is not exercised within three years from the time when the patentee comes to know the damage and the identity of the infringer or if the right is not exercised within 20 years from the time of the tortious act, pursuant to the provisions of the statute of limitations provided in the Civil Code of Japan, which is a general law. Please note that the above prescription period may be renewed, or the expiry of the prescription period may be postponed for statutory reasons.
Although there is no discovery procedure in Japan, the Patent Act provides that a court can order a party to produce documents upon the other party’s request for the purposes of:
However, this will not apply where the accused infringer possessing the documents has reasonable grounds to refuse to produce them.
If the court needs to assess whether reasonable grounds exist, it may require the document holder to present them for in-camera review. Furthermore, on 1 July 2019, the amended Patent Act introduced a procedure in which the court can determine the necessity of document production by way of in-camera procedures. The amended Patent Act also introduced a procedure allowing expert advisers to participate.
Moreover, by way of the 2019 amendment to the Patent Act, an inspection system was introduced on 1 October 2020, under which an inspector designated by the court will be entitled to enter into the factories, offices, etc, of a defendant and collect evidence necessary to make a decision on the existence of facts regarding the alleged infringement. However, the requirements for conducting an inspection are strictly stipulated as follows:
A complaint must contain both parties’ names and addresses, the plaintiff’s lawyer’s name and address (if appointed), the gist of the demand and the grounds for the demand. Specifically, the complaint must detail each accused product and alleged infringing act, describe the product’s relevant features, and compare them to each claim element. In general, supportive evidence – to prove both the act of infringement and the relevant features of the product – is submitted with the complaint. A patentee is expected to conduct a sufficiently detailed investigation and analysis of a case prior to initiating a lawsuit to identify these facts and find the relevant evidence.
No special provisions for lawsuits in intellectual property proceedings differ from those for non-intellectual property proceedings.
It is acceptable to supplement pleadings with additional arguments. A court examines the case through periodic hearings (generally once a month), and each party is allowed to present its legal/factual arguments or evidence during these proceedings. The plaintiff may even expand or amend the claim or statement of claim until oral arguments are concluded. However, the courts may limit such additional arguments or evidence if they consider that they would substantially delay court proceedings.
The legal system does not allow for representative or collective actions for intellectual property rights proceedings, although if the subject matter of the suits is common to two or more persons or is based on the same factual or statutory cause, these persons may sue or be sued as co-parties.
Civil Code
As an abuse of rights is prohibited under the Civil Code, the same will apply to the execution of patent rights, and therefore, where the execution of such rights is abusive, that execution will be restricted.
For example, the act of filing a lawsuit may cause tort liability where such litigation is found to be significantly unreasonable in light of the purport of the litigation system (eg, the allegation of infringement is entirely baseless and the owner of the intellectual property right is fully aware of the lack of legal grounds). In addition, based on judicial precedents, a patent right-holder who has made a declaration of fair, reasonable and non-discriminatory (FRAND) terms will not be permitted to claim for an injunction or for licence fees against a party who intends to be licensed under FRAND terms beyond those terms, as this will fall under an abuse of rights.
Guidelines for the Use of Intellectual Property
In addition, the Japan Fair Trade Commission (JFTC) has stipulated that its Guidelines for the Use of Intellectual Property (IP Guidelines) under the Antimonopoly Act clearly set out the principles governing the use of intellectual property rights, including patent rights, under the Act. In January 2016, the JFTC partially amended the IP Guidelines and supplemented the descriptions related to standard essential patents under the Antimonopoly Act. If a patent right is exercised in a manner that violates these Guidelines, the act may constitute a violation of the Antimonopoly Act.
Unfair Competition Prevention Act
Furthermore, if the owner of the intellectual property right makes or disseminates a false allegation of infringement of that intellectual property right, that act could constitute an act of unfair competition under the Unfair Competition Prevention Act, and the owner of the intellectual property right may be subject to a claim for injunction and/or damages.
A patent owner and an alleged infringer are usually the necessary parties to patent infringement litigation. A registered exclusive licensee is entitled to file an action without the patent owner, based on an infringement of the registered exclusive licence, seeking the same remedies as the patent owner. In this regard, there are arguments over whether non-exclusive or non-registered exclusive licensees can initiate an action for infringement.
Regarding injunctions, it is generally understood that neither a non-registered exclusive licensee nor a non-exclusive licensee has the right to seek an injunction. However, when it comes to claims for damages, a non-registered exclusive licensee can pursue such claims, while a non-exclusive licensee is not permitted to seek damages.
For a direct infringement to be constituted, the product in question needs to satisfy all of the component features of a patented invention. If any one of the constituent features is not satisfied, a direct infringement has not been constituted.
However, even if the product does not satisfy all the component features, the following cases will constitute indirect infringement and thus constitute patent right infringement.
In any instances where direct or indirect infringement is constituted, a patentee may claim injunctions and damages against an infringer. In a claim for damages, provisions such as those on the presumption of the amount of damage or those on the presumption of negligence may be applied.
In the Japanese Patent Act, inventions are classified as:
An act of working on a patented invention is stipulated for each of these categories. Specifically, for the invention of a process, the act of using the process is specified as an act of working.
Additionally, for an invention that involves a process for producing a product, the following activities are considered acts of working:
Conversely, for an invention that pertains to a product, the acts of producing, using, assigning (including lending and providing via telecommunications lines), exporting, importing, or offering to assign the product itself are defined as acts of working.
No clear rule exists regarding whether patent infringement in Japan can be recognised when part of a process is executed abroad. In some cases where steps of a patented process were conducted outside Japan, a District Court ruled that this cannot be considered working the patent in Japan because the relevant technical steps of the patent are not completed within the country. However, this ruling is not regarded as a well-established precedent that applies universally to process inventions in Japan.
In principle, the scope for protection of a patent right (eg, the technical scope of a patented invention) is determined based on the statements in the scope of claims. In addition, the meaning of each term used in the scope of claims is interpreted in conjunction with the statements in the description and drawings. The prosecution history of the application and prior art may also be considered. Accordingly, to say that infringement of a patent right has taken place in principle, the subject product must satisfy all of the constituent features of the patented invention. However, even if the product does not satisfy all of the constituent features of the patented invention, there may be a case that amounts to indirect infringement or infringement under the doctrine of equivalents (see 3.2 Direct and Indirect Infringement).
Typical defences against an allegation of patent infringement include non infringement arguments and assertions of invalidity as a counter argument in the litigation, as well as the following.
If a patent right is exercised abusively, it can lead to certain defences for the accused party. For example, if a patent holder who has declared their commitment to FRAND (fair, reasonable, and non-discriminatory) terms later seeks an injunction against a party that intends to be licensed under those terms or demands damages exceeding what would normally be considered a fair licensing fee, the defendant may invoke the defence of abuse of rights.
If the defendant has practised a patented invention or prepared for such practice at the time of the patent application filing, the defendant can claim “prior use” as a defence.
If the patentee, when filing an application, makes assertions that exclude the technology that is to be included in the technical scope of a patented invention (based on the common meaning of the term being used), it is typical for the technical scope of the patented invention to be construed in a limited manner as a result.
Where the products in question were assigned from a patentee or person with legitimate rights, no patent infringement will be admitted, as the patent right will have been exhausted.
In addition, the defendant may claim that their use of the patented invention was experimental and, therefore, beyond the scope of the patent right.
Even though the Patent Act provides for three types of non-exclusive licences to be granted by the JPO Commissioner (eg, compulsory licences), as of the end of 2025, no such compulsory licence has ever actually been granted in Japan (see 2.2 Third-Party Remedies to Remove the Effects of Intellectual Property).
The fact that the defendant’s infringing conduct was an exercise of their patent right cannot be used as a defence against the patentee’s infringement claim.
As to the statute of limitations, the patentee cannot claim damages for an infringement if more than three years have passed since the date on which the patentee became aware of an infringement and the identity of the infringer who caused the damage. There is an overall limit of 20 years from the act of infringement (see 2.9 Special Limitation Provisions).
Experts involved in patent litigation are mainly judicial research officials and expert advisers.
Judicial research officials are full-time court employees who conduct examinations on technical matters necessary for judicial decisions and report to a judge. Judicial research officials are primarily appointed from the pool of JPO employees or patent lawyers.
Expert advisers are part-time employees appointed by the courts who get involved in proceedings to:
Expert advisers are usually involved in proceedings to arrange issues and evidence (preparatory proceedings, etc) and make oral explanations on technical matters. In patent litigation, to gain a proper understanding of technical issues, expert advisers are often involved and conduct technical explanation sessions during preparatory proceedings. It is common for an expert in the technical field to which a patented invention belongs (usually a university professor or patent lawyer) to be appointed as an expert adviser.
In addition, in litigation, experts selected by a party may prepare expert opinions, which are submitted as evidence by the party but rarely testify in court as witnesses.
There is no separate procedure for claim construction in Japan.
A system allowing the court to seek third-party opinions in patent infringement lawsuits was introduced on 1 April 2022. According to Article 105.2-11 of the Patent Act, if a party requests it and the court finds it necessary, the court may request the public to submit documents stating public opinions on the application of the Patent Act or any other necessary matters after hearing the other party’s opinion. It is envisioned that this system will be used in patent infringement cases where the judgments may have significant impacts not only on an industry to which the parties belong but also on companies in other industries.
Case No 2018 (Ne) 10046
In the recent Case No 2018 (Ne) 10046, the Intellectual Property High Court issued a request for third-party opinions for the first time. In this case, the patent at issue claimed a certain system comprising a server and a plurality of terminal devices. The issue here was whether or not the defendant’s act of creating a new system can be considered “production” (a form of working of invention as defined in Article 2(3)(i) of the Patent Act) of the patented system, even when the server in the alleged infringing system is located outside Japan. The court issued the request for third-party opinions regarding whether the defendant’s act can be considered “production” of the patented system and, if so, what requirements are necessary for it to fall under the category of “production”. Various organisations have submitted multiple statements in response to the court’s request for opinions. The IP high court eventually determined infringement in its judgment, whereas the district court, in the first instance, denied the “working of invention” within Japan.
Case No 2023 (Ne) 10040
The latest case in which the Intellectual Property High Court issued a request for third-party opinions is Case No 2023 (Ne) 10040, which concerns a patented invention for a breast augmentation composition containing multiple drug substances. According to Article 69(3) of the Patent Act, the effect of a patent right for an invention related to “a pharmaceutical product to be produced by mixing two or more drugs” does not extend to “acts of preparation performed based on a prescription by a physician or dentist.”
In this case, the court has requested third-party opinions, such as whether the act of a nurse or assistant nurse mixing multiple drugs to produce a combined medication, as instructed by a physician without issuing a prescription, can constitute an “act of preparation performed based on a prescription by a physician or dentist”.
Patents
There are two procedures available for seeking the revocation/cancellation of a patent – namely, an opposition or an invalidation trial before the JPO.
Anyone may file an opposition within six months from the issue date of a patent Gazette based on the following grounds:
An interested party may file an invalidation trial at any time after a patent has been granted, even if it has expired, based on the following grounds:
Utility Models
There is only one procedure for revocation/cancellation of a utility model registration: an invalidation trial before the JPO.
An interested party may file an invalidation trial at any time after a utility model has been granted, even after the utility model has expired, based on the following grounds:
In Japan, an opposition or an invalidation trial for a patent or a utility model registration may be filed for each individual claim.
Amendments (“corrections” in opposition or invalidation proceedings under the Patent Act or the Utility Model Act) may be filed in opposition or invalidation proceedings.
In opposition proceedings, a patent owner may file amendments in the period for responding to a notice of cancellation issued by the board of trial examiners who examined the request for opposition.
In invalidation trial proceedings, the owner of a patent or utility model right may file amendments in the period for filing an answer in response to a request for an invalidation trial. The owner may also file amendments in the period for responding to a notice of reasons for invalidation or an advance notice of appeal decision, both issued by the board of trial examiners who examined the request for invalidation trial.
In patent or utility model infringement litigation heard before the courts, both infringement and invalidation issues may be heard together because the defendant may challenge the validity of a patent or utility model registration as a defence before a court. The courts examine both infringement and validity together and render a decision based on their examination.
There are no specifically applicable provisions regarding trial and settlement in intellectual property rights proceedings. However, in practice, the trial will be divided into two parts. At the first stage (the examination of infringement), the court focuses on determining whether the infringement of the intellectual property right is established. At the second stage (the stage for examination of damages), a court will assess the damages incurred by a plaintiff only after it has tentatively concluded the establishment of the infringement.
In this regard, the Intellectual Property Division of the Tokyo District Court has a trial model for patent infringement litigation. According to this trial model, it is assumed that six court hearing dates are held at the first stage (stage for examination on infringement). If courts find no patent infringement, they will either:
If courts find that there is patent infringement, the courts will either:
It is assumed that three court hearing dates are held at the second stage, and both parties present arguments and counterarguments with regard to the amount of damages. Then, the courts will either:
However, as the progress of trials (including the number of court hearing dates) depends largely on the complexity of cases, trials rarely proceed as envisioned in the above trial model – and in complex cases, trials are often prolonged for much longer than the trial model.
According to statistics provided by the Intellectual Property High Court, the average time intervals from commencement to disposition in intellectual property-related civil cases in 2024 were 14.5 months (in all district courts) and 7.1 months (in all high courts).
In patent litigation, examination of fact witnesses or experts is rarely conducted. In cases of examination of witnesses, opportunities for cross-examination are provided.
A case is determined solely by a legal judge. The Japanese legal system has neither technical judges nor jury trials for intellectual property cases.
At the Tokyo and Osaka District Courts, there are special divisions for intellectual property matters (four at the Tokyo District Court and two at the Osaka District Court), where judges experienced in intellectual property matters hear and decide cases. The judges in these courts and the IPHC do not necessarily have technical backgrounds; the courts retain judicial research officials with technical backgrounds to help judges understand any technology issues involved in a case (see 3.6 Role of Experts). The courts can also appoint and request expert advisers to assist judges with any case involving advanced, complicated or specialised technology issues.
Parties cannot influence who will judge a case, although a party can request to avoid a certain judge if they have reason to believe that said judge cannot be impartial due to a particular relationship with the other party (eg, being a relative of one party).
A judge usually takes the initiative in settlement negotiations unless the parties clearly refuse to settle a case. In no event will a defendant be obliged to settle a case. Generally, courts prefer settlements rather than judgments to resolve cases. A judge may disclose or imply their unofficial, tentative opinion on a case to the parties in order to facilitate settlement negotiations. A judge will cease settlement negotiations if one party decides to request a court decision rather than a settlement.
Even if there are any pending parallel revocation or infringement proceedings, the current proceedings will not normally be stayed, and the courts will make a separate judgment in each case. The courts can even dismiss a claim for infringement on the grounds that the patent is invalid, without the need for a revocation proceeding. Therefore, it is possible for a conflict between two cases on the same subject matter to exist. However, in practice, the High Court, as the court of the second instance, will make consistent judgments so that any contradiction in the first instance will be resolved.
There have been no cases in Japan in which anti-suit injunctions have been issued against litigation and it is unclear whether Japanese courts would take foreign anti-suit injunctions into account. In addition, in Japan, there is no statutory basis for granting injunctions against litigation by patentees, and there have been no examples of Japanese courts recognising anti-suit injunctions.
Remedies Available for the Patentee
Typical remedies available to a patentee include injunctive relief and damages. As part of injunctive relief, the patentee can request necessary measures to prevent further infringement, which may include the disposal of the infringing goods. While lawyers’ fees can be recovered as part of the damages, this recovery is quite limited – typically around 10% of the total amount of actual damages awarded by the courts.
A patentee is only entitled to seek compensatory damages, as claims for enhanced damages, such as punitive damages, are not permitted, even in cases of willful infringement. The Patent Act establishes certain presumptions for calculating damages based on the profits generated from the infringement or the expected royalties. Ultimately, a judge has the discretion to determine the appropriate remedies or the amount of damages, but this discretion is limited to the amount claimed by the plaintiff.
In addition, where an applicant has given a warning, together with documents stating the contents of the invention claimed in the patent application, that applicant may also claim compensation equivalent to the licence fee against any person who has worked the invention as a business after the warning and before the registration of the patent. Furthermore, even without such a warning, the applicant may claim compensation against those who, while aware that the invention relates to a published patent application, have worked the invention as a business before the registration. The right to claim compensation may only be exercised after the patent has been registered.
A patentee may also demand measures necessary to restore its business credibility, but this remedy is rarely used.
Enforcement of Remedies
The methods for the enforcement of remedies depend on the contents of those remedies. For example, with respect to judgments ordering patent infringers to pay damages, the remedies are enforced by seizing the infringers’ property and receiving dividends from proceeds from auctions, etc. With regard to judgments ordering patent infringers to cease and desist from manufacturing the infringing products, if the infringers do not perform the obligations ordered in the judgment, the court in charge of enforcement will enforce the remedies by ordering the infringers to pay to the obligees certain amounts of money which are found to be reasonable for securing performance of the obligation.
If a defendant prevails, the courts can order the plaintiff to pay court costs (eg, transportation fees to attend court hearings, expenses for delivering documents and daily allowances for witnesses); however, such costs do not include the defendant’s legal fees or other costs incurred by the defendant in the course of the procedure. There is no right or remedy for a prevailing defendant to recover their own costs.
A prevailing defendant may seek damages arising out of the infringement litigation, including their lawyers’ fees if the litigation itself is considered to constitute a tort on the grounds that it is found to be unreasonable (eg, if an allegation of patent infringement is entirely baseless and the patentee is fully aware of the lack of legal grounds). However, the courts rarely accept such a claim.
There are no different remedies for different types of technical intellectual property in Japan.
In an effort to stop the execution of an injunction granted at first instance, an infringer will (upon filing an appeal) have to file a petition to seek a ruling on the suspension of compulsory execution. Here, the infringer will need to provide a security deposit (to be returned after litigation).
Under Japanese law, injunctions are enforceable pending appeal. However, in practice, when infringers file an appeal, they also file a motion for suspension of compulsory execution in most cases, and such suspensions are usually granted if the motion is filed.
The above refers to judgments for injunctions of the first instance in main lawsuits. On the other hand, if right-owners request preliminary injunctions separately from (or in parallel with) the main lawsuits and the first instance courts grant the requests and issue preliminary injunction orders, it is difficult to stop enforcement of such preliminary injunction orders in practice, although there is a legal way to challenge such preliminary injunction orders (see 2.7 Interim Injunctions).
Generally, there are no special provisions concerning the appellate procedure for patent litigation. However, the IPHC has exclusive jurisdiction over appeals from decisions made by the Tokyo District Court and the Osaka District Court on patent litigations. A court normally consists of three judges, but if the case includes an important issue of law, five judges may sit to consider the matter and deliver their opinion.
As the court of the second instance, the IPHC reviews not only issues of law but also the facts from the proceedings in District Courts in the first instance. The IPHC may also conduct its own factual findings. A party may submit additional legal arguments, facts or evidence to the appeal court, unless such an additional claim is considered to be causing delay to the procedure and to be that party’s fault. However, the Supreme Court, as the court of final instance, only reviews the legal issues of a case.
With respect to patent infringement litigation in Japan, costs normally incurred are for:
Stamp fees and expenses for delivering documents are required in order to file a lawsuit in Japan. The amount of stamp fees is calculated according to a formula prepared by the court based on the value of the subject matter of the suit.
In general, the losing party typically pays court costs – including stamp fees, expenses for delivering documents, and daily allowances for witnesses. However, the allocation of these costs is at the court’s discretion. The court may also assign a portion of the costs to the winning party based on the extent to which their claims were not accepted.
It should be noted that court costs do not include lawyers’ fees, and thus, generally speaking, each party must bear its own lawyers’ fees. A plaintiff may seek compensation for their lawyer’s fees as part of damages, but the recovery rate is left to the court’s discretion and is usually quite limited, even if the plaintiff wins the case (in practice, around 10% of the total amount of actual damages admitted by the courts).
Alternative dispute resolution (ADR) is not commonly used to settle intellectual property cases in Japan. However, ADR, such as mediation or arbitration, is available, and JIPAC and IACT (see 2.4 Specialised Bodies/Organisations for the Resolution of Disputes) are the ADR organisations that provide dispute resolution in the field of intellectual property.
Moreover, the Tokyo District Court and the Osaka District Court introduced mediation procedures for IP rights matters on 1 October 2019. This procedure is designed to resolve disputes regarding IP rights matters in a speedy and efficient manner by using a mediation committee composed of a judge from the special division for intellectual property matters and experts, such as lawyers or patent attorneys, who orally express their opinions. In principle, the procedure should be concluded within around three hearing dates.
Patent rights may be freely assigned. However, no assignment will take effect unless it has been registered in the patent registry, except in cases of general succession, such as inheritance or merger. Where a patent right is jointly owned, no joint owner may assign their share without the consent of all the other joint owners. Neither an agreement in writing nor JPO approval is required to conduct an assignment.
Assignment of a patent right takes effect upon registration in the patent registry. In the case of a general succession, such as through inheritance or merger, the assignment takes effect without being registered, but the registration is made by providing notification of that assignment.
In terms of licensing patent rights, licences are granted merely by an agreement between the parties (non-registered licences) and licences granted upon registration at the JPO (registered as exclusive licences), in addition to an agreement between the parties. As for the former type of licence, there are no particular restrictions regarding formalities, such as the existence of a written agreement or notification to the JPO. However, the latter type of licence requires registration with the JPO to enter into force. It should be noted that if a registered exclusive licence is granted, other parties may not execute the scope of rights subject to that grant (even the patent right-holder).
As the grant of a registered exclusive licence requires registration at the JPO in order for it to come into force, it is necessary to make an application to the JPO setting forth the content of the licence agreed by both parties and to receive registration thereof. The granting of a non-registered licence comes into force merely by way of the execution of an agreement between the parties. Thus, generally, a licence of this kind is granted by preparing a licence agreement, as well as orally or even implicitly.
23rd Floor, Roppongi Hills Mori Tower
6-10-1 Roppongi
Minato-ku
Tokyo
106-6123
Japan
+81 3 6438 5511
+81 3 6438 5522
info_general@tmi.gr.jp ww.tmi.gr.jp
Intellectual Property High Court Grand Panel
This article introduces the Grand Panel decision dated March 19, 2025 (Intellectual Property High Court Case No. 2023 (Ne) 10040) concerning patents in the field of aesthetic medicine. The case focused on three main issues:
The Grand Panel overturned the original ruling by the lower court, partially acknowledged infringement, and especially provided a clear framework for interpreting issues (ii) and (iii).
The Grand Panel held that an invention of a “product” intended for administration to the human body should not automatically be treated as a “method invention” related to medical practices and denied industrial applicability. It reasoned that, historically, the 1975 amendment to the Patent Act deleted the old Article 32(2), which excluded “inventions such as pharmaceuticals” from patent eligibility. Therefore, it would be difficult to interpret the law as excluding inventions involving administration to the human body, especially since Article 29 contains no explicit exclusion for such items.
Furthermore, the court noted that inventions involving “substances derived from a person and ultimately returned to that person” do not necessarily mean that collection, preparation, and administration are inseparable. In light of developments in regenerative medicine and gene therapy, it is clear that not only physicians but also pharmaceutical and related industries play a significant role in research and development. Thus, the court emphasised the need for patent protection to promote technological advancement. Accordingly, it concluded that the invention in question qualifies as “industrially applicable.”
This decision significantly clarifies that inventions involving materials collected from and returned to patients, such as those in regenerative medicine, should not be easily reclassified as “medical methods” and excluded from patentability under Article 29. Even in fields where blood collection, mixing, and administration seem unified, the manufacturing component aligns with industrial realities, particularly in the pharmaceutical and medical materials sectors. The court affirmed the importance of patent protection as a driver of innovation.
Article 69(3) of the Patent Act stipulates that patent rights related to “medicines to be mixed and manufactured for diagnosing, treating, or preventing human disease” do not extend to dispensing acts based on physicians’ prescriptions. In this case, the court determined that the composition was used for breast augmentation with a primarily aesthetic purpose. In line with common definitions, the court stated that “disease” implies a condition in which physiological or mental dysfunction impedes a healthy daily life. Cosmetic breast enhancement does not meet this criterion, so the composition was not considered a “medicine” under this article. Therefore, regardless of whether a prescription was involved, the exemption under Article 69(3) did not apply.
The court also noted that Article 69(3) was enacted in conjunction with the repeal of the old Article 32(2) and was intended to ensure the smooth practice of medicine by preserving physicians’ freedom to choose medications. However, the court held that this public interest rationale cannot be extended to the selection of drugs for cosmetic purposes. The reason for this judgment appears to be that drugs used for cosmetic purposes cannot be regarded as those used for the treatment of diseases, and that cosmetic medicine is generally elective and not medically necessary, and thus does not justify the same level of professional discretion as medical treatments.
The ruling precisely defined “medicine” based on both statutory language (disease-related use) and common word meaning, confirming that drugs for cosmetic or aesthetic purposes are generally excluded from protection under Article 69(3). It reaffirmed that how the intended use is described in the specification and claims is directly relevant to the application of Article 69(3). Moreover, the court emphasised that the teleological interpretation, which aims to preserve the smooth practice of medicine, should apply only to contexts relevant to disease diagnosis or treatment.
As a result, in aesthetic medical practice, where compositions are prepared in-house, Article 69(3) cannot generally be relied on for exemption, making patent risk assessment and licensing strategies increasingly important. On the other hand, for compositions mixed for purposes of reconstructive medicine (eg, following breast cancer or burns) or disease treatment, the application of Article 69(3) may still be considered on a case-by-case basis.
In conclusion, this decision interpreted the requirement for industrial applicability by considering legislative history and industrial realities, and it strictly limited the scope of dispensing exemptions to the statutory definition and legislative purpose. The decision is precedent-setting for compositions involving autologous materials and in-house mixing in aesthetic medicine and has direct implications for licensing practices, infringement risk management, compliance, and R&D investment planning.
Supreme Court Decision
The Supreme Court’s rulings become established precedents in the interpretation of Japanese law. On March 3, 2025, the Supreme Court rendered judgments in two lawsuits alleging patent infringement involving a video distribution system equipped with a function for displaying comments over videos:
These two cases involve DWANGO filing lawsuits against FC2, alleging that the internet-based, comment-enabled video distribution service “FC2 Video,” operated by FC2, infringed DWANGO’s patent rights and seeking injunctions and damages.
In both lawsuits, the issue was whether FC2’s act of distributing its files from a server in the USA to user terminals in Japan, through FC2’s systems for online video delivery services with commentary (“FC2’s act”), infringes DWANGO’s patents. In both instances, the High Court overturned the District Court’s conclusions. Ultimately, the Supreme Court ruled in favour of DWANGO, recognising that FC2 had infringed DWANGO’s patents.
Below is a comparison of the key points of the two lawsuits.
Patents alleged to be infringed
Case No 2025 (Ju) 14 and 15:
Case No 2025 (Ju) 2028:
Provisions of the Patent Act
Case No 2025 (Ju) 14 and 15:
Case No 2025 (Ju) 2028:
Territoriality of patent rights
Patent rights are granted in each country in accordance with that country’s legal system. The existence, transfer, and effect of patent rights are determined by the laws of the respective country, and their effect is recognised only within that country’s territory. This is known as the principle of territoriality of patent rights.
On the other hand, it is generally required that all elements constituting a patented invention be practised by the infringer for patent infringement to be established; this is known as the all-elements rule.
The Supreme Court established an important legal standard regarding the relationship between the principle of territoriality and the all-elements rule, stating as follows:
"While the effect of a Japanese patent right is recognized only within the territory of Japan, in today’s world, where cross-border transmission of information via telecommunication lines has become extremely easy, if a program or the like is transmitted from outside Japan and thereby made available within Japanese territory via a telecommunication line, it would be inconsistent with the purpose of the Patent Act, to contribute to the development of industry by granting patent holders exclusive rights to work their patented inventions as a business, thereby protecting and promoting inventions, if such acts were always deemed to be outside the scope of Japanese patent rights solely because the transmission originated from abroad. Therefore, even in such cases, if the act in question, when viewed as a whole, can be substantively evaluated as constituting a “provision through a telecommunication line,” an “assignment, etc.,” or “production” within Japanese territory, then there is no reason to deny the applicability of Japanese patent rights to that act. *In this context, “assignment, etc.” refers to the assignment of the product that is the subject of the invention."
The Supreme Court did not concretely elaborate on the legal standard, but its application to the two cases suggests that it affirmed the existence of patent infringement by emphasising the key points outlined below.
As a judicial precedent related to the principle of territoriality, though concerning trademark rights, the Intellectual Property High Court, in KIYOMURA CORPORATION v Daisho Japan Co., LTD (Case No 2024 (Ne) 10031), concluded that the defendant did not infringe the plaintiff’s trademarks, such as “SUSHI ZANMAI.”
In relation to territoriality, the court noted that the sushi restaurants operated by the defendant were located in Singapore and Malaysia. Accordingly, the use of indications such as “SUSHI ZANMAI” by the defendant was not considered to be in connection with the provision of services within Japan, and therefore did not infringe the source-identifying function of the plaintiff’s trademark rights within Japan.
While this case is quite different from the Supreme Court’s decision on patent infringement, it is consistent with the Court’s reasoning, which focused on the invention’s effect and economic impact in Japan.
Technology
Pantech Corporation v Google Japan G.K. Case No 2023 (Wa) 70501
On June 23, 2025, the Tokyo District Court issued a ruling in a patent infringement case, ordering an injunction to halt the sale of Google’s Pixel 7. This decision has attracted attention because it recognises Google’s infringement of a Standard Essential Patent (SEP) for implementing a standardised technology in its product.
A SEP refers to a patent that is essential to implement a technological standard, meaning that manufacturing a product compliant with the standard inevitably requires the use of the patented invention. Such patents are typically subject to procedures established by Standard Setting Organisations (SSOs), including a FRAND declaration, and a commitment by the patent holder to license the SEP to all users of the standard on fair, reasonable, and non-discriminatory terms.
In this case, it was claimed that Google’s smartphone Pixel 7 (the “Google product”) infringed the Long Term Evolution (LTE)-related SEP owned by the plaintiff, and a request was made to enjoin the sale of the Google product. While the case also involved disputes over whether the patent was actually infringed (satisfaction of the claim elements) and whether the invention met the standard of inventive step, the court affirmed both. The main issue was whether, in light of the patent’s SEP status, the exercise of the right to seek an injunction constituted an abuse of rights.
As a legal standard, the Tokyo District Court stated:
“When a SEP holder seeks an injunction against an implementer of the standard based on a SEP, such a request should be deemed an abuse of rights unless there are special circumstances indicating that the implementer has no intention to obtain a license on FRAND terms.”
The court then concluded that there was indeed an abuse of rights in this case, citing the factors outlined below.
On the other hand, in Pantech Corporation v Asus Japan (Case No 2024 (Wa) 7976), decided on April 10, 2025, the court rejected Pantech’s request for an injunction, finding that there were no exceptional circumstances indicating that ASUS Taiwan lacked the intention to obtain a license under FRAND terms. The court also denied Pantech’s claim for damages exceeding the reasonable royalty amount based on FRAND terms.
Furthermore, the court noted that despite prior negotiations and settlement discussions during the litigation, the parties failed to reach an agreement on FRAND royalty rates because the rates proposed by each party were too far apart. The court attributed this discrepancy to differences in legal precedent:
In major countries worldwide, court precedents such as [2020] UKSC 37, Unwired Planet International Ltd and another v Huawei Technologies (UK) Co Ltd and another and others have evolved and influenced the international standard for calculating FRAND royalties.
In contrast, Japan has seen no significant development in case law on FRAND royalty calculation for nearly a decade since the Apple-Samsung Grand Panel decision, resulting in a lack of well-established methodologies in Japanese practice to determine FRAND royalty rates.
This divergence in judicial perspectives and practical standards highlights an interesting contrast in how different courts now assess the precedential value of the Apple-Samsung Grand Panel decision.
Life sciences
In 2025, several significant rulings were issued by the Japanese Courts, including the Intellectual Property High Court (the “IP High Court”) in the field of life sciences. The case below shows the criteria for determining the scope of effectiveness of a pharmaceutical patent right whose term has been extended.
In Japan, the scope of protection of a pharmaceutical patent whose term has been extended is governed by the Grand Panel decision of the IP High Court dated January 20, 2017 (the “Oxaliplatin Case Decision”). The scope of an extended patent has since been determined in accordance with the criteria set forth in that decision. However, in applying those criteria to specific cases, it is not always clear how far the concept of “substantially identical” should extend.
The decision introduced below concerns a case in which an additive or modified component, not the active ingredient, was changed, and it offers certain insights in this regard. The decision also attracted attention because it awarded damages of CNY21.7 billion.
Toray Industries, Inc v Sawai Pharmaceutical Co., Ltd., Fuso Pharmaceutical Industries, Ltd. Case No 2021 (Ne) 10037, Intellectual Property High Court (decision rendered on 27 May 2025)
Overview of the case
The plaintiff is a pharmaceutical company that manufactures an original (brand-name) drug and is the holder of a patent titled “Antipruritic Agent.” The plaintiff sought damages from the defendants, each a generic drug manufacturer, alleging that the manufacture and sale of the defendants’ products infringed the plaintiff’s extended patent right.
The patented invention concerns an antipruritic agent whose active ingredient is a certain compound, and its purpose is to provide an antipruritic agent with a very rapid and strong antipruritic effect. While the patented invention uses the compound “nalfurafine” (the “compound at issue”) as its active ingredient, the defendants’ products use “nalfurafine hydrochloride” as the active ingredient. Whether the defendants’ formulations satisfied the claims of the patented invention and whether the formulations were “substantially identical” thereto were the central issues in dispute.
Patent Term Extension in Japan
In Japan, a patent expires 20 years from the filing date (Patent Act, Article 67).
However, because pharmaceuticals require lengthy regulatory review before approval, the patent term may be extended for up to five years (Article 67(4)).
The effectiveness of a patent right that has been extended, however, does not cover acts other than the working of the patented invention for the product that was the subject of the regulatory approval forming the basis for the extension (or, where a specific use is designated in that approval, a product used for that use) (Article 68-2). In the case of pharmaceutical patents, the “regulatory approval” referred to above is approval under the Pharmaceuticals and Medical Devices Act.
Accordingly, whether the defendant’s product infringes the extended patent right requires two inquiries:
For the second inquiry, Article 68-2 of the Patent Act and the standards set forth in the “Oxaliplatin Case Decision” guide the analysis. Under that decision, the effectiveness of an extended patent right extends not only to the pharmaceutical product specified by the regulatory approval – defined by its “ingredients, quantity, dosage, administration method, indications, and effects” – but also to products that are substantially identical to it as pharmaceuticals.
Decision
Whether the defendants’ products fall within the technical scope of the patented invention
The Tokyo District Court, which heard the case at first instance, held that the “active ingredient” as a claim element of the patented invention referred to the active pharmaceutical ingredient (API) that serves as the basis of the formulation before any additives are combined. Because the defendants’ products used hydrochloride as an active ingredient, the court concluded that it did not satisfy this claim element and therefore did not fall within the scope of the patented invention.
The Intellectual Property High Court held that the defendants’ products fell within the technical scope of the patented invention.
Its reasoning was as follows.
On these grounds, the court concluded that the defendants’ products meet the claim element and are included within the technical scope of the patented invention.
Whether the extended patent right covers the defendants’ products
The Court in this case followed the Oxaliplatin Case Decision in holding that the effect of an extended patent right covers not only the pharmaceutical product specified by its “ingredients, quantity, dosage, administration method, indications, and effects,” but also products that are deemed “substantially identical”.
It then reasoned as follows.
Based on these reasons, the Court held that the defendants’ formulations are substantially identical, as a pharmaceutical, to the plaintiff’s formulation that was the subject of the regulatory approval underlying the patent term extension and therefore infringe the plaintiff’s extended patent right.
It should be noted that the defendants have filed an appeal to the Supreme Court, and the forthcoming decision is being closely watched.
Osaka Dojimahama Tower 15th floor
1-1-27 Dojimahama
Kita-ku
Osaka 530-0004
Japan
+81 6 6676 8834
+81 6 6676 8839
nakatsukasa_n@clo.gr.jp www.clo.jp/english/